The graph👇is from evenity phase 3 clinical trial. It is dual-action based on bone turnover markers with a net anabolic effect obvious in early stages, although bmd kept increasing in later half of the year-long treatment. However the interpretation is up to everyone. The advantages or disadvantages of the hypothesized “modeling based” bone building by evenity, i.e., building new bones at quiescent bone surface, is yet to be studied scientifically.